AX-2026-042520 · Liraglutide · ERP lot ERP-2601-P6802

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.54	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.46	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — des-palmitoyl liraglutide (−238 Da)	0.93	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	3748.9631	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3748.9582	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.3	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.35	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	9.72	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.56	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	2.56	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partial shrinkage from vial wall	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.07	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	17.21	min	17.28 ± 0.40 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.15	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	73,391	—	≥ 20,000	PASS
Resolution to nearest impurity	vs γ-Glu regioisomer	1.57	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 73,391, and skew follows the reported asymmetry factor of 1.15. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.93 % impurity against a 98.54 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Liraglutide — main peak	17.21	4,789,349	98.54	—
2	des-palmitoyl liraglutide (−238 Da)	13.77	45,201	0.93	-238.230
3	des-His1 truncate (−137 Da)	16.19	12,151	0.25	-137.059
4	deamidated (Asn→Asp, +1 Da)	16.73	7,776	0.16	+0.984
5	γ-Glu regioisomer	17.62	3,888	0.08	0.000
6	liraglutide dimer	20.36	972	0.02	+3748.963
7	palmitoyl bis-adduct (+238 Da)	20.09	972	0.02	+238.230
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3748.9631 Da, computed from C172H265N43O51. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3748.9582 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	625.8345	625.8336	-0.0009	7.6
5+	750.7999	750.7989	-0.0010	49.8
4+	938.2481	938.2468	-0.0013	100.0
3+	1250.6616	1250.6600	-0.0016	54.2
2+	1875.4888	1875.4864	-0.0024	8.4

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.95	98.54	divergence +0.47 pp vs batch median
Total impurities (% area)	not stated	1.46
Largest single impurity (% area)	not stated	0.93
Water (%)	3.6	4.35
Counter-ion (%)	not stated	9.72
Peptide content (%w/w)	98.6	not determined
Endotoxin (EU/mg)	not stated	2.56
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (24 d) → laboratory (courier, cold pack, 11 d) → assay.
Assay date: 04 May 2026
Submitted to the index: 22 May 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot ERP-2601-P6802 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042518	ERP-2601-P6802	Janoshik	2026-Q2	98.47	4.05	—	Supplier-supplied	1	MARGINAL
AX-2026-042519	ERP-2601-P6802	Janoshik	2026-Q2	98.88	4.41	95.2	Supplier-supplied	1	MARGINAL
AX-2026-042521	ERP-2601-P6802	Janoshik	2026-Q2	98.11	4.55	90.6	Buyer-sourced	3	MARGINAL
AX-2026-042522	ERP-2601-P6802	Medutest	2026-Q2	98.21	4.94	101.3	Supplier-supplied	1	MARGINAL
AX-2026-042523	ERP-2601-P6802	Janoshik	2026-Q2	98.45	4.85	94.4	Supplier-supplied	1	MARGINAL
AX-2026-042524	ERP-2601-P6802	Janoshik	2026-Q2	98.81	5.09	—	Supplier-supplied	1	MARGINAL
AX-2026-042525	ERP-2601-P6802	Janoshik	2026-Q2	98.48	4.40	95.6	Supplier-supplied	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Liraglutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	WWB	WWB-2607-X2189	Nordanalyt	2026-Q3	99.61	5.03	97.3	Supplier-supplied	0	PASS
AX-2026-043335	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.29	4.91	—	Laboratory-retained	1	FAIL
AX-2026-043332	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.16	4.88	91.3	Supplier-supplied	1	FAIL
AX-2026-041271	WWB	WWB-2607-X2189	Medutest	2026-Q3	99.93	5.24	95.8	Supplier-supplied	0	PASS
AX-2026-043336	CPC	CPC-2602-G1978	Janoshik	2026-Q3	97.69	4.58	104.9	Supplier-supplied	1	MARGINAL
AX-2026-041652	QSC	QSC-2605-W8602	Nordanalyt	2026-Q3	99.33	6.55	—	Supplier-supplied	0	PASS
AX-2026-041273	WWB	WWB-2607-X2189	Janoshik	2026-Q3	99.87	4.27	—	Supplier-supplied	0	PASS
AX-2026-041272	WWB	WWB-2607-X2189	Janoshik	2026-Q3	99.15	4.12	97.2	Supplier-supplied	0	PASS

Other recent ERP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042574	TB-500	ERP-2605-S8022	VendorInvestigate	2026-Q3	99.54	2.91	96.4	Buyer-sourced	1	MARGINAL
AX-2026-042535	Tesamorelin	ERP-2604-W7280	Janoshik	2026-Q3	99.19	3.89	92.7	Supplier-supplied	1	MARGINAL
AX-2026-042577	TB-500	ERP-2605-S8022	Janoshik	2026-Q3	99.51	3.45	—	Supplier-supplied	1	MARGINAL
AX-2026-042542	Tesamorelin	ERP-2604-W7280	Janoshik	2026-Q3	98.54	4.58	103.1	Supplier-supplied	2	FAIL
AX-2026-042547	Survodutide	ERP-2605-E7682	PeptideMeter	2026-Q3	98.25	5.44	93.0	Supplier-supplied	1	MARGINAL
AX-2026-042540	Tesamorelin	ERP-2604-W7280	Kestrel	2026-Q3	99.72	3.47	103.2	Supplier-supplied	1	MARGINAL
AX-2026-042575	TB-500	ERP-2605-S8022	Janoshik	2026-Q3	99.93	3.36	95.5	Supplier-supplied	0	PASS
AX-2026-042539	Tesamorelin	ERP-2604-W7280	Janoshik	2026-Q3	98.77	4.30	89.9	Buyer-sourced	2	MARGINAL